{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:09:04Z","timestamp":1788876544912,"version":"build-2803163510"},"reference-count":98,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR161219"],"award-info":[{"award-number":["NIHR161219"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Late-onset Pompe disease is a rare inherited genetic condition that causes progressive muscle dysfunction and damage. As the disease advances, the progressive weakening of respiratory muscles significantly increases the risk of respiratory failure, which is a major contributor to premature mortality. Enzyme replacement therapy is the primary treatment for Pompe disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical impact of enzyme replacement therapies for the treatment and management of late-onset Pompe disease and establish the relative effectiveness of enzyme replacement therapy compared to best supportive care (in the absence of enzyme replacement therapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and network meta-analysis of published evidence on the clinical effectiveness of enzyme replacement therapy and best supportive care was undertaken. Comprehensive bibliographic database searches were conducted up to May 2024 to identify randomised controlled trials or any other prospective enzyme replacement therapy studies in patients with Pompe disease. Network meta-analyses of randomised controlled trials were undertaken to estimate indirect treatment effects for forced vital capacity % predicted and the 6-minute walk test. Other studies were summarised using narrative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review included 60 studies: 38 on enzyme replacement therapy and 22 on best supportive care. Enzyme replacement therapy studies comprised 3 randomised controlled trials, 3 randomised controlled trial extensions, 7 registry studies and 25 single-group prospective studies. Two randomised controlled trials had a high risk of bias. Best supportive care studies included 14 longitudinal and 8 cross-sectional studies.<\/jats:p>\n                    <jats:p>In the network meta-analyses, after approximately 1 year, enzyme replacement therapy-naive patients showed significant 6-minute walk test improvements versus placebo: ~25\u2005m with alglucosidase alfa and ~54\u2005m with avalglucosidase alfa. No significant differences were found for forced vital capacity % predicted or comparisons with cipaglucosidase alfa, although very few enzyme replacement therapy-naive patients taking cipaglucosidase alfa were available for inclusion in the analyses. Intra-enzyme replacement therapy comparisons showed a significant 6-minute walk test advantage for avalglucosidase alfa. However, a sensitivity analysis adjusting for skewed data revealed no significant differences.<\/jats:p>\n                    <jats:p>Long-term enzyme replacement therapy effectiveness was assessed in single-group studies, showing initial gains maintained for 1\u20133 years, followed by gradual 10- to 15-year declines in 6-minute walk test and forced vital capacity % predicted. However, small sample sizes and missing data introduce uncertainty.<\/jats:p>\n                    <jats:p>Long-term evidence on best supportive care is limited, with most of the evidence focused on characterising basic demographic information and support needs. A small number of studies reported declines in forced vital capacity % predicted. Formal comparisons with long-term enzyme replacement therapy studies were not possible, but declines appear to be similarly gradual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The network meta-analyses shows enzyme replacement therapy modestly improves 6-minute walk test and forced vital capacity % predicted after 1 year versus placebo in enzyme replacement therapy-naive patients. However, there is limited evidence to suggest meaningful differences in outcomes between alglucosidase alfa, avalglucosidase alfa and cipaglucosidase alfa with miglustat. Observational data suggest declines beyond 2\u20133 years, lasting up to 15 years. Long-term comparative effectiveness remains uncertain, as does enzyme replacement therapy\u2019s impact on disease progression and supportive care needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme as award number NIHR161219.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/gjrh0730","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:18:49Z","timestamp":1753885129000},"page":"1-58","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-1493","authenticated-orcid":true,"given":"Mark","family":"Corbett","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4114-2227","authenticated-orcid":true,"given":"Chinyereugo","family":"Umemneku-Chikere","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-2709","authenticated-orcid":true,"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5901-1101","authenticated-orcid":true,"given":"Nyanar Jasmine","family":"Deng","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":true,"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":true,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-8412","authenticated-orcid":true,"given":"Chong Yew","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-2581","authenticated-orcid":true,"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-0512","authenticated-orcid":true,"given":"Rachel","family":"Churchill","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"key2026090817580500_ref1-bib1","doi-asserted-by":"crossref","first-page":"768-e31","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"key":"key2026090817580500_ref2-bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"key2026090817580500_ref3-bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ODRR.S69109","article-title":"Pompe disease: clinical perspectives","volume":"7","author":"Cabello","year":"2017","journal-title":"Orphan Drugs Res Rev"},{"key":"key2026090817580500_ref4-bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med"},{"key":"key2026090817580500_ref5-bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"key2026090817580500_ref6-bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann Transl Med"},{"key":"key2026090817580500_ref7-bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"key2026090817580500_ref8-bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-021-01836-y","article-title":"Quality of life and its contributors among adults with late-onset Pompe disease in China","volume":"16","author":"Chen","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref9-bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s41669-019-0142-3","article-title":"A systematic review of the health economics of Pompe disease","volume":"3","author":"Schoser","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"key2026090817580500_ref10-bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref11-bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","article-title":"Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up","volume":"39","author":"Gungor","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref12-bib12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"key2026090817580500_ref13-bib13","author":"Deegan"},{"key":"key2026090817580500_ref15-bib15","volume-title":"Letter: National Designation and Funding of the Service for Patients with Lysosomal Storage Disorders","author":"Stallibrass","year":"2004"},{"key":"key2026090817580500_ref16-bib16","volume-title":"Myozyme","author":"Sanofi Genzyme","year":"2021"},{"key":"key2026090817580500_ref17-bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2026090817580500_ref18-bib18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2026090817580500_ref19-bib19","volume-title":"Package \u2018rjags\u2019: Bayesian Graphical Models Using MCMC","author":"Plummer","year":"2024"},{"key":"key2026090817580500_ref20-bib20","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"key2026090817580500_ref21-bib21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"key2026090817580500_ref22-bib22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"key2026090817580500_ref23-bib23","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","article-title":"104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)","volume":"271","author":"Schoser","year":"2024","journal-title":"J Neurol"},{"key":"key2026090817580500_ref24-bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref25-bib25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"key":"key2026090817580500_ref26-bib26","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1007\/s00415-024-12489-9","article-title":"Changes in forced vital capacity over \u2264 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry","volume":"271","author":"Berger","year":"2024","journal-title":"J Neurol"},{"key":"key2026090817580500_ref27-bib27","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","article-title":"Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start","volume":"267","author":"Stockton","year":"2020","journal-title":"J Neurol"},{"key":"key2026090817580500_ref28-bib28","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/j.jval.2020.08.1742","article-title":"PRO6 characteristics of late onset Pompe disease patients in Latin America: a patient registry analysis","volume":"23","author":"Marcondes","year":"2020","journal-title":"Value Health"},{"key":"key2026090817580500_ref29-bib29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref30-bib30","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1212\/WNL.0000000000207547","article-title":"Characteristics of patients with late-onset Pompe disease in France: insights from the French Pompe Registry in 2022","volume":"101","author":"Lefeuvre","year":"2023","journal-title":"Neurology"},{"key":"key2026090817580500_ref31-bib31","doi-asserted-by":"crossref","first-page":"e16292","DOI":"10.1111\/ene.16292","article-title":"Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: a French cohort study","volume":"31","author":"Tard","year":"2024","journal-title":"Eur J Neurol"},{"key":"key2026090817580500_ref32-bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nmd.2023.10.001","article-title":"Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry","volume":"34","author":"Martinez-Marin","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref33-bib33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref34-bib34","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol"},{"key":"key2026090817580500_ref35-bib35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.23340","article-title":"New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy","volume":"45","author":"Angelini","year":"2012","journal-title":"Muscle Nerve"},{"key":"key2026090817580500_ref36-bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref37-bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cells11030334","article-title":"Six-minute walk distance is a useful outcome measure to detect motor decline in treated late-onset Pompe disease patients","volume":"11","author":"Claeys","year":"2022","journal-title":"Cells"},{"key":"key2026090817580500_ref38-bib38","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1212\/WNL.88.16_supplement.P1.120","article-title":"Long-term efficacy of alglucosidase alfa in late-onset Pompe disease","volume":"88","author":"Clemens","year":"2017","journal-title":"Neurology"},{"key":"key2026090817580500_ref39-bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref40-bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","article-title":"Home-based infusion of alglucosidase alfa can safely be implemented in adults with late-onset Pompe disease: lessons learned from 18,380 infusions","volume":"37","author":"Ditters","year":"2023","journal-title":"Biodrugs"},{"key":"key2026090817580500_ref41-bib41","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/gim.2018.2","article-title":"Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study","volume":"20","author":"Hahn","year":"2018","journal-title":"Genet Med"},{"key":"key2026090817580500_ref42-bib42","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"key2026090817580500_ref43-bib43","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S0149-2918(07)80460-7","article-title":"Initial therapy response of 6 months of enzyme replacement therapy in 11 juvenile\/adult M. Pompe patients","volume":"29","author":"Hartung","year":"2007","journal-title":"Clin Ther"},{"key":"key2026090817580500_ref44-bib44","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"key2026090817580500_ref45-bib45","doi-asserted-by":"crossref","first-page":"e0208854","DOI":"10.1371\/journal.pone.0208854","article-title":"The ACE I\/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease","volume":"13","author":"Kuperus","year":"2018","journal-title":"PLOS ONE"},{"key":"key2026090817580500_ref46-bib46","doi-asserted-by":"crossref","first-page":"793566","DOI":"10.3389\/fcell.2022.793566","article-title":"Bioimpedance phase angle as a prognostic tool in late-onset Pompe disease: a single-centre prospective study with a 15-year follow-up","volume":"10","author":"Ravaglia","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"key2026090817580500_ref47-bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2012.05.016","article-title":"Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis?","volume":"107","author":"Ravaglia","year":"2012","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref48-bib48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref49-bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"key":"key2026090817580500_ref50-bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-018-0824-4","article-title":"Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients","volume":"13","author":"van der Meijden","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref51-bib51","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","article-title":"Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy","volume":"41","author":"van der Meijden","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref52-bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref53-bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","article-title":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: evaluating the European POmpe Consortium stop criteria","volume":"30","author":"van Kooten","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref54-bib54","first-page":"26","article-title":"Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease","volume":"26","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"key2026090817580500_ref55-bib55","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","article-title":"Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"271","author":"Byrne","year":"2023","journal-title":"J Neurol"},{"key":"key2026090817580500_ref56-bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nmd.2016.05.018","article-title":"Progression from respiratory dysfunction to failure in late-onset Pompe disease","volume":"26","author":"Berger","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref57-bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref58-bib58","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.clinthera.2011.05.051","article-title":"Survival and prognostic factors prior to enzyme replacement therapy in 302 children and adults with Pompe disease","volume":"33","author":"Gungor","year":"2011","journal-title":"Clin Ther"},{"key":"key2026090817580500_ref59-bib59","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","article-title":"Late-onset Pompe disease primarily affects quality of life in physical health domains","volume":"63","author":"Hagemans","year":"2004","journal-title":"Neurology"},{"key":"key2026090817580500_ref60-bib60","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","article-title":"Course of disability and respiratory function in untreated late-onset Pompe disease","volume":"66","author":"Hagemans","year":"2006","journal-title":"Neurology"},{"key":"key2026090817580500_ref61-bib61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10545-011-9320-x","article-title":"Burden of illness of Pompe disease in patients only receiving supportive care","volume":"34","author":"Kanters","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref62-bib62","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref63-bib63","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1183\/09031936.05.00020005","article-title":"Respiratory insufficiency and limb muscle weakness in adults with Pompe\u2019s disease","volume":"26","author":"Pellegrini","year":"2005","journal-title":"Eur Respir J"},{"key":"key2026090817580500_ref64-bib64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.20665","article-title":"Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy","volume":"35","author":"Slonim","year":"2007","journal-title":"Muscle Nerve"},{"key":"key2026090817580500_ref65-bib65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":"Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease","volume":"19","author":"Van der Beek","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref66-bib66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref67-bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref68-bib68","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"key2026090817580500_ref69-bib69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype\u2013phenotype correlation in Pompe disease, a step forward","volume":"9","author":"De Filippi","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref70-bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"key2026090817580500_ref71-bib71","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"key":"key2026090817580500_ref72-bib72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nmd.2007.03.006","article-title":"Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale","volume":"17","author":"Hagemans","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref73-bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1469-8749.2003.tb00966.x","article-title":"Pompe disease and physical disability","volume":"45","author":"Haley","year":"2003","journal-title":"Dev Med Child Neurol"},{"key":"key2026090817580500_ref74-bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2012.09.017","article-title":"Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening","volume":"107","author":"Rigter","year":"2012","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref75-bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref76-bib76","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"key2026090817580500_ref77-bib77","first-page":"S152","article-title":"Efficacy and safety of cipaglucosidase alfa\/miglustat versus alglucosidase alfa\/placebo in late-onset Pompe disease: PROPEL study","volume":"8","author":"Schoser","year":"2021","journal-title":"J Neuromusc Dis"},{"key":"key2026090817580500_ref78-bib78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-023-02715-4","article-title":"Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study","volume":"18","author":"Ditters","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref83-bib83","doi-asserted-by":"crossref","first-page":"107185","DOI":"10.1016\/j.ymgme.2022.107185","article-title":"Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial","volume":"138","author":"Kishnani","year":"2023","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref84-bib84","first-page":"A17","article-title":"Efficacy and safety of avalglucosidase alfa in participants with late-onset pompe disease after 145 weeks\u2019 treatment: Phase 3 COMET trial","volume":"5","author":"Henderson","year":"2023","journal-title":"BMJ Neurol Open"},{"key":"key2026090817580500_ref85-bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1363849031000139298","article-title":"Development of a disease-specific disability instrument for Pompe disease","volume":"6","author":"Haley","year":"2003","journal-title":"Pediatr Rehabil"},{"key":"key2026090817580500_ref86-bib86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-024-03156-3","article-title":"Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease","volume":"19","author":"Claeys","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"key2026090817580500_ref87-bib87","volume-title":"Eur J Neurol","author":"Lika","year":"2024"},{"key":"key2026090817580500_ref88-bib88","doi-asserted-by":"crossref","first-page":"e240045","DOI":"10.57264\/cer-2024-0045","article-title":"Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data","volume":"13","author":"Shohet","year":"2024","journal-title":"J Comp Eff Res"},{"key":"key2026090817580500_ref90-bib90","doi-asserted-by":"crossref","first-page":"108121","DOI":"10.1016\/j.ymgme.2023.108121","article-title":"Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naive adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial","volume":"141","author":"Toscano","year":"2024","journal-title":"Mol Genet Metab"},{"key":"key2026090817580500_ref91-bib91","article-title":"Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 97 weeks of treatment during the COMET trial","volume":"4","author":"Henderson","year":"2022","journal-title":"BMJ Neurol Open"},{"key":"key2026090817580500_ref92-bib92","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.3233\/JND-159054","article-title":"Quality of life and participation in the daily life (activities) of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up","volume":"2","author":"Gungor","year":"2015","journal-title":"J Neuromusc Dis"},{"key":"key2026090817580500_ref93-bib93","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3233\/JND-159060","article-title":"A phase 4 prospective study in patients with adult Pompe disease treated with alglucosidase alfa","volume":"2","author":"Thurberg","year":"2015","journal-title":"J Neuromusc Dis"},{"key":"key2026090817580500_ref94-bib94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref95-bib95","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.94.15_supplement.695","article-title":"NEO1 and NEO-EXT studies: long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients","volume":"94","author":"Dimachkie","year":"2020","journal-title":"Neurology"},{"key":"key2026090817580500_ref96-bib96","first-page":"S64","article-title":"NEO1\/NEO-EXT: safety and exploratory efficacy of repeat avalglucosidase alfa dosing for up to 6 years in participants with late-onset Pompe disease","volume":"62","author":"Dimachkie","year":"2020","journal-title":"Muscle Nerve"},{"key":"key2026090817580500_ref97-bib97","first-page":"486","article-title":"NEO1\/NEO-EXT studies: trends over time in exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5.5 years in late-onset Pompe disease (LOPD) patients","volume":"27","author":"Schoser","year":"2020","journal-title":"Eur J Neurol"},{"key":"key2026090817580500_ref98-bib98","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.nmd.2020.08.012","article-title":"Autophagic myopathies\/myofibrillar myopathies\/distal myopathies\/Pompe disease: P.03 NEO1\/NEO-EXT studies: safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in late-onset Pompe disease (LOPD)","volume":"30","author":"Schoser","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref99-bib99","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.nmd.2022.07.130","article-title":"FP.17 Long-term follow-up of cipaglucosidase alfa\/miglustat in ambulatory patients with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"32","author":"Schoser","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref100-bib100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1212\/WNL.0000000000202282","article-title":"Long-term follow-up of cipaglucosidase alfa\/miglustat in ambulatory patients with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"100","author":"Mozaffar","year":"2023","journal-title":"Neurology"},{"key":"key2026090817580500_ref101-bib101","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.nmd.2019.06.306","article-title":"O.23A 10 year prospective study on the effects of enzyme replacement therapy in adult Pompe patients","volume":"29","author":"Harlaar","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"key2026090817580500_ref102-bib102","first-page":"40","article-title":"Variable effects of enzyme replacement therapy in adults with Pompe disease: a 10 year prospective study","volume":"26","author":"Harlaar","year":"2019","journal-title":"Eur J Neurol"},{"key":"key2026090817580500_ref103-bib103","first-page":"242","article-title":"Variable effects of enzyme replacement therapy in adults with Pompe disease: 10 years\u2019 follow-up","volume":"42","author":"Harlaar","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"key2026090817580500_ref104-bib104","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.nmd.2023.07.336","article-title":"Safety of home administration of cipaglucosidase alfa+miglustat in late-onset Pompe disease: results from multiple clinical trials","volume":"33","author":"Byrne","year":"2023","journal-title":"Neuromuscul Disord"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJRH0730\/GJRH0730.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:29:20Z","timestamp":1788874160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/GJRH0730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":98,"alternative-id":["10.3310\/GJRH0730"],"URL":"https:\/\/doi.org\/10.3310\/gjrh0730","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"05-2024","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"04-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"07-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}